Insider Transactions in Q3 2024 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q3 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
246
+0.21%
|
$17,958
$73.17 P/Share
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
35,604
-1.62%
|
$2,563,488
$72.85 P/Share
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,604
+3.12%
|
$427,248
$12.73 P/Share
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
32,699
-1.48%
|
$2,387,027
$73.22 P/Share
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,699
+2.88%
|
$555,883
$17.57 P/Share
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,513
-1.84%
|
$2,957,449
$73.63 P/Share
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,513
+3.52%
|
$688,721
$17.57 P/Share
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,713
-2.08%
|
$1,680,762
$74.59 P/Share
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,713
+2.04%
|
$386,121
$17.57 P/Share
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
28,680
-2.61%
|
$2,122,320
$74.46 P/Share
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,680
+2.54%
|
$487,560
$17.57 P/Share
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
39,380
-1.78%
|
$2,953,500
$75.03 P/Share
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,380
+3.43%
|
$669,460
$17.57 P/Share
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
53,013
-1.19%
|
$4,028,988
$76.7 P/Share
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,013
+4.51%
|
$901,221
$17.57 P/Share
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,714
-38.65%
|
$1,403,550
$75.08 P/Share
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+27.88%
|
$673,704
$36.89 P/Share
|